Atlas Trials

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Clinical trial NCT03558503 · COMPLETED

Trial details

NCT number
NCT03558503
Sponsor
UroGen Pharma Ltd.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
Start date
2018-10-15
Primary completion
2020-01-03
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.